



NATURAL PRODUCTS AND DRUG DISCOVERY

AN INTEGRATED APPROACH

Edited by

Subhash C. Mandal

Vivekananda Mandal

Tetsuya Konishi

Natural Products and Drug Discovery

An Integrated Approach

Edited By

Subhash C. Mandal

Professor
Division of Pharmacognosy
Department of Pharmaceutical Technology
Jadavpur University
Kolkata, India

Vivekananda Mandal

Assistant Professor
Division of Pharmacognosy
Institute of Pharmaceutical Sciences
Guru Ghasidas University (A Central University)
Bilaspur, India

Tetsuya Konishi

Professor Emeritus
Niigata University of Pharmacy & Applied Life Sciences (NUPALS)
Tojima, Akiha-ku, Niigata, Japan
&
Director, Office HALD Food Function Research
Sakai, Nishi-ku, Niigata, Japan



Elsevier

Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2018 Elsevier Ltd. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-08-102081-4

For information on all Elsevier publications visit our website at
<https://www.elsevier.com/books-and-journals>



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

Publisher: Mica Haley

Acquisitions Editor: Anneka Hess

Editorial Project Manager: Michelle W. Fisher

Production Project Manager: Poulouse Joseph

Designer: Matthew Limbert

Typeset by TNQ Books and Journals



Contents

List of Contributors	xix
Foreword	xxiii
Preface	xxv

Section I

Traditional Medicine and Drug Discovery

1. Drug Discovery From *Ayurveda*: Mode of Approach and Applications

Tuhin K. Biswas

1. AYUSH and <i>Ayurveda</i>	3
2. Chronological Genesis of Ayurvedic Drugs for Therapeutic Application	4
3. Fundamental Principles of Personalized Medicine, Genetic Study, and Applied Aspects of Ayurvedic Pharmacodynamics	14
4. Classification of Ayurvedic Therapeutics	15
4.1 Ayurvedic Treatment for the Promotion of Health	15
4.2 Treatment for the Prevention of Disease	16
4.3 Curative Management in <i>Ayurveda</i>	17
5. Scientific Research of <i>Ayurveda</i> for Drug Development From Plant Sources	20
5.1 <i>Rasayana</i> Therapy	20
5.2 Diabetes Mellitus	20
5.3 Wound-Healing Drugs	21
5.4 Learning, Memory, and Cognitive Disorders	21
6. Scientific Research of <i>Ayurveda</i> for Drug Development From Metals and Minerals	22
6.1 Drugs From Zinc: <i>Jasada Bhasma</i>	23
6.2 Iron Therapy in <i>Ayurveda</i>	23
6.3 Gold Therapy in <i>Ayurveda</i>	24
6.4 Shilajit: A Unique Molecule of <i>Ayurveda</i>	24
7. Recommendation	25
References	26

2. Traditional and Folk Medicine as a Target for Drug Discovery

Sujata Wangkheirakpam

- | | | |
|----|--|----|
| 1. | Introduction | |
| 2. | Different Traditional and Folk Medicines | 29 |
| | 2.1 Ayurveda | 32 |
| | 2.2 Maibarom | 33 |
| | 2.3 Traditional Chinese Medicine | 35 |
| | 2.4 Traditional Korean Medicine | 35 |
| | 2.5 African Medicine (Muti in South and Ifa in West) | 36 |
| | 2.6 Iranian Medicine | 37 |
| 3. | Taxol as a Lead to Cancer Drug Discovery | 37 |
| 4. | Demand for Drugs for Liver Disorders (Hepatic Disease) | 38 |
| 5. | Demand for Drugs for Dengue | 42 |
| | 5.1 Targeting —and Controlling the Virus | 45 |
| | 5.2 Targeting —and Controlling the Vector Mosquito | 47 |
| 6. | Conclusion | 48 |
| | References | 51 |

3. Bioactivity-Guided Phytofractions: An Emerging Natural Drug Discovery Tool for Safe and Effective Disease Management

Partha Palit

- | | | |
|----|---|----|
| 1. | Introduction | 57 |
| 2. | Why Do Bioactivity-Guided Phytofractions Exhibit Promising Alleviation Against Disease Models | 59 |
| 3. | Separation, Characterization, and Standardization of Target Disease-Specific Bioactivity-Guided Fractions | 63 |
| 4. | Significance and Utility of Target-Oriented, Disease-Specific, Bioactivity-Guided Phytofractions | 63 |
| 5. | Experimental Evidence in Favor of Bioassay-Guided Phytofraction as a Therapeutic Tool | 66 |
| 6. | Discussion and Conclusion | 67 |
| | Acknowledgments | 69 |
| | References | 69 |

4. Development of Chinese Herbal Health Products for the Prevention of Aging-Associated Diseases

Pou K. Leong, Jihang Chen, and Kam M. Ko

- | | | |
|----|--|----|
| 1. | Mitochondrial Dysfunction in Aging-Associated Diseases | 73 |
| | 1.1 Cardiovascular Diseases | 74 |
| | 1.2 Neurodegenerative Diseases | 75 |
| | 1.3 Osteoporosis | 76 |
| | 1.4 Dysregulation of Immune Function | 77 |

2.	Conceptual Basis of Preventive Health in Chinese Medicine	79
2.1	Yin-Yang Theory	79
2.2	Qi and Body Function	80
2.3	Restoring the Dynamic Balance Between Yin and Yang and Hence the Generation of Normal Qi Using Chinese Tonifying Herbs	82
3.	Pharmacological Basis of the Health-Promoting Actions of Chinese Tonifying Herbs	84
3.1	Yang/Qi-Invigorating Action: Effects on Cellular Energy Metabolism and Mitochondrial Function	84
3.2	Yin-Nourishing/Blood-Enriching Action: Effects on Immune and Blood/Circulatory Functions	88
4.	Chinese Herbal Tonifying Formulas	90
4.1	Wu-Zi-Yan-Zong-Wan (Yang-Invigorating)	90
4.2	Er-Zhi-Wan (Yin-Nourishing)	92
4.3	Shengmai San (Qi-Invigorating)	92
4.4	Si-Wu-Tang (Blood-Enriching)	93
5.	Conclusions	95
	References	96
5.	Ethnobotany/Ethnopharmacology, and Bioprospecting: Issues on Knowledge and Uses of Medicinal Plants by Moroccan People	
	<i>Mostafa Elachouri</i>	
1.	Introduction	105
2.	Brief History of Medical Sciences in Muslim-Arab Civilization	106
2.1	Sciences at a Glance in the Golden Age	106
3.	Traditional Medicine in Morocco	111
3.1	Current Medical Ethnobiological Studies in Morocco	112
3.2	Knowledge of Ethnobotany, Ethnomedicine, and Medicinal Plant Uses	113
3.3	The Trading of Medicinal Plants	114
4.	Constraints and Challenges Facing the Medicinal Plants Sector	115
5.	Conclusion	116
	References	116
6.	Chemotaxonomy of Medicinal Plants: Possibilities and Limitations	
	<i>Ram Singh and Geetanjali</i>	
1.	Introduction	119
2.	Secondary Metabolites as Guide for Classifications	120
2.1	Alkaloid in Chemotaxonomy	120
2.2	Plant Phenol in Chemotaxonomy	124
2.3	Quinones in Chemotaxonomy	126
2.4	Glycosides in Chemotaxonomy	127

3. Limitations of Chemotaxonomic Classification
4. Summary and Future Prospects
- References

Section II

Leads From Natural Products

7. The Role of Natural Products From Plants in the Development of Anticancer Agents

Danielle Twilley and Namrita Lall

1. Introduction
2. Natural Products and Their Anticancer Activity
 - 2.1 Terpenoids
 - 2.2 Flavonoids
 - 2.3 Alkaloids
3. Plant-Derived Anticancer Drugs Currently in Use and in Clinical Trials
 - 3.1 Vincristine and Vinblastine
 - 3.2 Etoposide and Teniposide
 - 3.3 Paclitaxel and Docetaxel
 - 3.4 Topotecan and Irinotecan
 - 3.5 Elliptinium
 - 3.6 Homoharringtonine
4. Cell Line Abbreviations
5. Conclusion
- References

8. Plant Drugs in the Treatment of Osteoporosis

Sudhir Kumar and Rakesh Maurya

1. Introduction
2. Global Burden of Osteoporosis
3. Markers of Bone Metabolism
 - 3.1 Markers of Bone Formation
 - 3.2 Markers of Bone Resorption
4. Screening Assays for Osteoporosis
 - 4.1 Osteoblast Cultures
 - 4.2 Osteoclast Cultures
 - 4.3 The Ovariectomy Rat Model
5. Osteoprotective Plant Formulations
6. Active Constituents From Plants
 - 6.1 Flavonoids
 - 6.2 Isoflavonoids
 - 6.3 Lignans
 - 6.4 Coumarins
 - 6.5 Alkaloids
 - 6.6 Conclusions
- References

9. Phytodrugs and Immunomodulators for the Therapy of Leishmaniasis

C. Benjamin Naman, Ciro M. Gomes, and Gaurav Gupta

1.	Leishmaniasis	213
1.1	Overview of the Disease	213
1.2	Epidemiology	214
1.3	Life Cycle	215
1.4	Disease Manifestation	216
1.5	Immunological Alterations in Host	221
2.	Therapeutic Agents for Leishmaniasis	222
2.1	Current Antileishmanial Drugs	222
2.2	Drug Resistance	225
2.3	Drug Toxicity and Side Effects	226
2.4	Polychemotherapy for Leishmaniasis	227
2.5	Herbal Remedies	228
3.	Drug Targets in <i>Leishmania</i>	228
3.1	Polyamine Pathway	228
3.2	Thiol Metabolism	230
3.3	Sterol Pathway	230
3.4	Glucose Metabolism	231
3.5	Proteasome Pathway	232
4.	Approaches for Drug Screening of Natural Product Libraries Against <i>Leishmania</i>	233
4.1	Fluorescence Activated Cell Sorter–Based Assays	234
4.2	Plate Reader–Based Assays	234
4.3	Microscopy-Based High Content Assay	236
4.4	Animal Models Suitable for Drug Discovery and Development	236
5.	Phytochemicals With Antileishmanial and Immunomodulatory Activities	237
5.1	Natural Products Drug Discovery	237
5.2	In Vivo Antileishmanial Phytochemicals	239
5.3	Antileishmanial Crude Plant Extracts	244
5.4	Plant Natural Product In Vitro Antileishmanial Agents and Immunomodulators	245
5.5	Marine and Fungal Natural Products With In Vitro Antileishmanial Activity	254
5.6	Combination Therapy	255
6.	Future Directions and Conclusions	257
	References	258

10. Natural Products Targeting Inflammation Processes and Multiple Mediators

G. David Lin and Rachel W. Li

1. Inflammation Responses and Pathways
 - 1.1 Cellular Changes of Inflammatory Responses
 - 1.2 Signaling Mediators of Inflammatory Responses
 2. Common Mediators of Inflammation Pathways
 - 2.1 Eicosanoids
 - 2.2 Protein Kinase—Mediated I κ B Degradation in the NF- κ B Pathway
 - 2.3 Inducible NO
 - 2.4 Proinflammatory and Antiinflammatory Cytokines
 - 2.5 Antiinflammatory Drugs Targeting Common Mediators
 3. Natural Products Targeting the Common Inflammatory Mediators
 - 3.1 Introduction and the Salicylate Story
 - 3.2 Phenolics
 - 3.3 Terpenes
 - 3.4 Alkaloids
 - 3.5 Others
 4. Antiinflammatory Natural Products With Multiple Targets
 - 4.1 Introduction
 - 4.2 Curcumin
 - 4.3 (–)-Epigallocatechin-3-gallate
 - 4.4 *trans*-Resveratrol
 - 4.5 Quercetin
 - 4.6 Racemosic Acid
 5. Conclusion
- References

11. Biologically Functional Compounds From Mushroom-Forming Fungi

Hirokazu Kawagishi

1. Antidementia Compounds
 2. Antimethicillin-Resistant *Staphylococcus aureus* Compounds
 3. Osteoclast-Forming Suppressing Compounds
 4. Diarrhea-Causing Compounds
 5. Acetaldehyde Dehydrogenase Inhibitors
 6. Hyaluronan-Degradation Regulating Compounds
 7. Acute Encephalopathy Caused by Eating Angel's Wing Oyster Mushroom
- References

12.	Natural Products in Lifestyle Diseases: In Vitro Screening	
	<i>Anuradha S. Majumdar and Sahil J. Somani</i>	
1.	Introduction	327
1.1	Natural Products in Drug Discovery	327
1.2	Natural Products: Metabolic Disorders (Diabetes, Dyslipidemia, and Obesity)	328
1.3	Natural Products: Cardiovascular Disorders	336
1.4	Natural Products: Hypertension	338
1.5	Natural Products: Stroke	339
1.6	Natural Products: Cancer	340
1.7	Natural Products: Osteoarthritis and Chronic Obstructive Pulmonary Disease	342
2.	Summary	343
	References	343
13.	Common Toxic Plants and Their Forensic Significance	
	<i>Nawal K. Dubey, Abhishek K. Dwivedy, Anand K. Chaudhari, and Somenath Das</i>	
1.	Historical Aspect of Poisonous Plants	349
2.	Common Toxic Plants	350
3.	Impacts of Poisonous Plants on Grazing Animals	351
4.	Toxic Plants of Forensic Significance	358
5.	Detoxification of Plant Poison	363
6.	Therapeutic Use of Poisonous Plants	363
7.	Conclusion	367
	Acknowledgment	368
	References	368
14.	Role of Stress in Diseases and Its Remedial Approach by Herbal and Natural Products in Stress-Related Disease Management: Experimental Studies and Clinical Reports	
	<i>Dhrubojyoti Mukherjee, Partha Palit, Shubhadeep Roychoudhury, Sukalyan K. Kundu, and Subhash C. Mandal</i>	
1.	Pathophysiology of Stress Response	376
2.	Impact of Psychological Stress on Occurrence of Diseases	378
2.1	Cardiovascular Diseases	378
2.2	Hypertension	379
2.3	Diabetes	380
2.4	Metabolic Syndrome	381

2.5	Stroke	385
2.6	Infertility	385
2.7	Polycystic Ovarian Syndrome	385
2.8	Pregnancy Outcomes and Miscarriages	385
2.9	Gastric Ulcer	385
2.10	Irritable Bowel Syndrome	385
2.11	Osteoporosis	385
2.12	Decreased Immunity and Delayed Wound Healing	385
2.13	Mental Diseases	385
2.14	Need for Herbal and Natural Drugs in the Management of Psychological Stress	385

3. Herbal Therapy

3.1	<i>Withania somnifera</i>	385
3.2	<i>Panax ginseng</i>	385
3.3	<i>Eleutherococcus senticosus</i>	385
3.4	<i>Magnolia officinalis</i> and <i>Phellodendron amurense</i> Combination	385
3.5	<i>Rhodiola rosea</i>	385
3.6	<i>Lavandula angustifolia</i>	385
3.7	<i>Bacopa monnieri</i>	385
3.8	<i>Ginkgo biloba</i>	385
3.9	<i>Ocimum sanctum</i>	385
3.10	Black Tea	385
3.11	Green Tea	385

4. Nutritional Therapy

4.1	Vitamin C	385
4.2	L-Lysine	385
4.3	L-Ornithine	385
4.4	Jerte Valley Cherries	385
4.5	Fish Oil	385
4.6	Soy Protein	385
4.7	Casein Tryptic Hydrolysate	385
4.8	Yoghurt	385
4.9	Whey Protein	385

5. Conclusion

Acknowledgments

References

15. Antiinflammatory Medicinal Plants: A Remedy for Most Disease Conditions?

Sunday O. Otimenyin

1. Inflammation

1.1	Agents That Trigger and Sustain Inflammation	396
1.2	Mechanism of Inflammation	396
1.3	Healing of Injured Tissue	396
1.4	Active Antiinflammatory Constituents in Plants	396

1.5	Inflammatory Mediator Inhibitors in Plants	415
1.6	Medicinal Plants That Prevent Cell/Tissue Injury	420
1.7	Cosmetic Effects of Analgesic and Antiinflammatory Medicinal Plants	421
1.8	The Role of Inflammation in Disease Conditions	422
2.	Inflammation in Disease Conditions	423
2.1	Alzheimer's Disease	423
2.2	Asthma	423
2.3	Cancer	423
2.4	Cardiovascular Disease	424
2.5	Inflammatory Bowel Disease	424
2.6	Rheumatoid Arthritis	425
2.7	Infection	425
2.8	Metabolic Syndrome	425
3.	Medicinal Plants With Antiinflammatory Properties	426
	References	427

Section III

Herbal Drug Research

16. Techniques and Technologies for the Biodiscovery of Novel Small Molecule Drug Lead Compounds From Natural Products

Phurpa Wangchuk and Alex Loukas

1.	Introduction	435
2.	Biological Resources and the Search Strategies for Novel Drug Lead Compounds	437
2.1	Biological Resources With Chemotherapeutic Compounds	437
2.2	Search Strategies for Novel Drug Lead Compounds	439
3.	Logical Framework Approaches for the Biodiscovery of Small Molecule Drug Lead Compounds	440
3.1	Selecting Biological Materials: Their Identification and Collection Processes	441
3.2	Metabolomics Studies of Crude Extracts: A Recent Development	444
3.3	Techniques for Separation, Isolation, and Structure Elucidation of Natural Products	448
3.4	Biological Activity Screening of Crude Extracts and Pure Compounds	454
4.	Conclusions and Future Directions	460
	References	460

17.	Herb and Drug Interaction	
	<i>Nilanjan Ghosh, Rituparna C. Ghosh, Anindita Kundu, and Subhash C. Mandal</i>	
1.	Introduction	467
2.	Pharmacokinetic Herb–Drug Interactions	468
2.1	Metabolism of Herbal Drugs by Intestinal Microflora	469
2.2	Hepatic Metabolism of Herbal Medicines	469
2.3	Phase I: Metabolism by the Cytochrome System	470
2.4	Induction and Inhibition of Metabolic Enzymes	471
2.5	Efflux of Drugs Through Efflux Transporters	472
2.6	Organic Anion-Transporting Polypeptide	473
3.	Pharmacodynamic Interactions	474
4.	Selected Clinical Herb–Drug Interactions	476
4.1	Grapefruit Juice	476
4.2	St. John's Wort	476
4.3	<i>Ginkgo biloba</i>	478
4.4	Garlic	479
4.5	Berberine	480
4.6	Licorice	481
5.	Approaches to Identify Herb–Drug Interactions	482
6.	Conclusion	483
	References	484
18.	Toxicity Studies Related to Medicinal Plants	
	<i>Kavimani Subramanian, Divya Sankaramourthy, and Mahalakshmi Gunasekaran</i>	
1.	Introduction	491
2.	Toxicity Studies Are Indispensable for Medicinal Plants	492
3.	Preparation of a Test Substance for Toxicity Studies	493
4.	Toxicity Studies: General Considerations	493
4.1	Gross Behavioral Studies	493
4.2	Conventional Methods for LD ₅₀ Determination	494
5.	Acute Toxicity Testing	494
5.1	Fixed Dose Procedure	494
5.2	Acute Toxic Class Method	495
5.3	Up and Down Procedure	495
5.4	Acute Inhalational Toxicity	496
5.5	Acute Inhalational Toxicity	496
5.6	Acute Dermal Toxicity	496
6.	Subacute Toxicity Studies	497
7.	Subchronic Toxicity Studies (OECD TG 408, 409, 411, 413)	498
8.	Chronic Toxicity Studies	498

9. Special Toxicity Studies	500
9.1 Acute Eye Irritation/Corrosion Test	500
9.2 Skin Sensitization Test	501
9.3 Prenatal Developmental Toxicity	501
9.4 Neurotoxicity Studies	501
9.5 Carcinogenicity Studies	502
9.6 Reproduction Toxicity Studies	502
References	502
19. Prebiotics: A Functional Food in Health and Disease	
<i>Dharmik Joshi, Somdatta Roy, and Sugato Banerjee</i>	
1. Gut Microbes	507
2. Factors Influencing the Composition of Gut Flora	507
3. Health Benefits of Prebiotics	511
3.1 Acute Gastroenteritis	511
3.2 Cancer	511
3.3 Mineral Absorption	513
3.4 Lipid Metabolism	513
3.5 Distant Effects of Prebiotics	516
References	519
20. Cultivation of Medicinal and Aromatic Plants	
<i>Ajay G. Namdeo</i>	
1. Introduction	525
2. Sustainable Development	526
3. Cultivation of Medicinal and Aromatic Plants	529
3.1 Methods of Propagation	529
3.2 Factors Affecting Cultivation of Medicinal Plant	541
4. Opportunities in Developing the Medicinal Plants Sector	547
4.1 Institutional Support	547
References	551
21. Digitization of Traditional Knowledge	
<i>Souvik Basak</i>	
1. Introduction	555
2. Why Digitization of Natural Products Is Necessary	555
2.1 Digital Databases on Traditional Knowledge (Web Based)	556
2.2 Bioinformatics-Guided Approach for Traditional Knowledge	556
2.3 Metadata Portals	581
3. Biodiversity Analysis	581

4.	Virtual Screening of Natural Products From Databases	
4.1	Screening Through Network Pharmacology	
4.2	Screening Through Cheminformatics	
5.	Bioinformatics Approach to the Digitization of Knowledge on Natural Products	
5.1	Quality Control of Herbals Using Next Gen Sequencing	
5.2	Expressed Sequence Tags	
5.3	Simple Sequence Repeats	
5.4	Constructing Network Biology Through Chemogenomics	
5.5	Network Biology Models—Distance-Based Mutual Information Model	
5.6	Quantitative Composition—Activity Relationship Study	
5.7	Network Target-Based Identification of Multicomponent Synergy	
5.8	Application of the Bioinformatics Approach for Drug Discovery From Traditional Plants	
5.9	In Silico Docking	
6.	InvertNet	
7.	Screening From Actinobacteria	
8.	Prediction Informatics for Secondary Metabolomes	
9.	Bioinformatics to Natural Products Through Synthetic Biology	
10.	eSNaPD, a Novel Web-Based Bioinformatics Tool	
11.	DNA Barcoding in Natural Products	
12.	Discussion and Conclusion	
	References	

22. **Good Agricultural Practices: Requirement for the Production of Quality Herbal Medicines**

Supradip Saha, Abhishek Mandal, and Anirban Dutta

1.	Introduction	
1.1	What Are Good Agricultural Practices?	
1.2	Why Good Agricultural Practices?	
2.	Basic Components of Good Agricultural Practices	
2.1	Hygiene and Cleanliness	
2.2	Prevention of Contamination	
2.3	Identification	
2.4	Efficacy	
2.5	Production and Income	
2.6	Sustainability	
2.7	Documentation and Traceability	
2.8	Social and Legal Concerns	
3.	Good Agricultural Practices for Medicinal Plants	
3.1	Identification	
3.2	Healthy Propagation Materials	

3.3	Agronomic Practices	615
3.4	Good Collection Practices	619
3.5	Postharvest Processing	620
3.6	Packaging and Labeling	621
3.7	Storage and Transportation	622
3.8	Sanitation	622
4.	Quality Control and Good Agricultural Practices	624
5.	Good Agricultural Practices: Ethical and Legal Considerations	629
6.	Epilogue	629
	References	630
23.	Fundamentals of Microwave-Based Sample Preparation for Plant-Based Drug Discovery	
	<i>Roshni Tandey, Kavi B.S. Chouhan, and Vivekananda Mandal</i>	
1.	Introduction	633
2.	Frequently Asked Questions	634
2.1	What Shall Be the Strategy for Plant Selection in the Case of Microwave-Assisted Extraction of Botanicals?	634
2.2	Is Any Special Preextraction Treatment Necessary for the Raw Material Before Subjecting It to Microwave-Assisted Extraction?	636
2.3	How Is Microwave-Assisted Extraction to Be Performed and Which Factors Need to Be Optimized and How?	636
2.4	How Can the Performance of the Microwave-Assisted Extraction Technique Be Monitored and Decisions Taken on the Optimum Set of Conditions?	637
2.5	How Can It Be Ensured That No Thermal Degradation Takes Place at the Optimum Operating Conditions?	638
2.6	How Is the Mechanism of Accelerated Extraction Phenomenon in the Case of Microwave Treatment Elucidated and How Can Its Complete Supremacy Over Conventional Methods Be Proved?	638
3.	Key Reminders for Microwave-Assisted Extraction of Botanicals	639
4.	Conclusion	640
	Acknowledgments	641
	Further Reading	642
	Author Index	643
	Subject Index	701

Fundamentals of Microwave-Based Sample Preparation for Plant-Based Drug Discovery

Roshni Tande, Kavi B.S. Chouhan, Vivekananda Mandal
Institute of Pharmacy, Guru Ghasidas Central University, Bilaspur, India

1. INTRODUCTION

Extraction is as simple as making a cup of tea, but rarely do we consider the steps involved in making of a cup of tea significant because the entire focus is on enjoying the flavor and taste of the tea prepared. Similarly, in natural product research rarely do we tend to realize the importance of selecting a judicious extraction process and the entire research is isolation or bioactivity driven. However, a few minutes of careful thinking can make us understand that an inappropriately selected extraction method is sufficient to jeopardize the entire objective of natural product research because any mistake can then make subsequent steps of isolation and bioactivity determination suffer heavily, thus leading to a shaky foundation. It is similar to optimizing the heating time for making tea. Imagine how tea would taste if heat were not applied at all but the ingredients were just macerated; equally, what would have been the taste if prolonged heating of a few hours were given for making tea. In today's modern technological era, no production line in the field of food and nutraceuticals is devoid of an extraction unit. After the recently concluded Paris Convention for Climate Change, strict protocols were drafted for limiting carbon contributions from each country, with heavy restriction being imposed on developed countries. In such a situation, technology and environment should be in tandem so that the greenness of planet earth is sustained by reducing emissions of greenhouse gases and the carbon load. This forms the backdrop for this chapter.

In recent times (from 2011) sufficient research has been done on designing and developing newer and greener extraction methods. In this regard, microwave-assisted extraction (MAE) needs no introduction. In one of our